15 March 2004 00:01 [Source: ICB Americas]
Novopharm Ltd., the wholly owned Canadian subsidiary of Teva Pharmaceutical Industries Ltd., plans to invest C$20 million to expand its Hood Road Penicillin production facilities in Markham, Ontario. The facility currently produces almost 40 penicillin products that are exported globally.
Since 1994, Novopharm has invested over $35 million at the Hood Road site to enhance its manufacturing and packaging capabilities. The latest move involves the purchase of property adjacent to the facility and investing in a warehousing facility, water purification system and upgrades to air systems within the plant.
With the upgrade, the plant will now serve the entire North American market for penicillin products, says a Novopharm spokesperson. The Mark-ham facility will absorb some of the capacity loss as a less efficient Teva Pharmaceuticals USA facility ramps down manufacturing.
The current project “represents our ongoing commitment toward ensuring all of our facilities meet the emerging needs of a global pharmaceutical market that continues to develop and mature,” says Allan Oberman, president and CEO of Novopharm.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
Asian Chemical Connections